Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...
Philadelphia-based Penn Medicine has developed a generative AI tool designed to help clinicians quickly identify and ...
The addition of agentic AI capital planning further strengthens TRIMEDX-AIQ as the intelligence layer powering smarter clinical asset decisions, helping systems reduce waste, optimize utilization, and ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...
UB is tapping AI’s incredible power to address global challenges by advancing education, research and outreach.
Indianapolis, Indiana, Dec. 15, 2025 (GLOBE NEWSWIRE) -- TRIMEDX today announced the launch of TRIMEDX-AIQ™ , a breakthrough AI intelligence offering that sets a new standard for clinical asset ...
Alzheimer’s Disease Analysis Model Generation 1 (ADAM-1) is a multi-agent reasoning large language model (LLM) framework designed to integrate and analyze multimodal data, including microbiome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results